Clinical trials: Levodopa
Parkinson's Disease
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinson's disease.
- Trial name
- NCT00253084
- Testing
- IPX054 200 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease (PD)
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04379050
- Testing
- ABBV-951
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 130 people
- Sponsor
- AbbVie
Parkinson Disease
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
The purpose of this project is to assess the change in dopamine transporter density in Parkinson's disease subjects during a sixty month period including a nine month treatment trial of levodopa.
- Trial name
- ELLDOPA (NCT00134784)
- Testing
- [123I]B-CIT SPECT imaging
- Volunteers
- 142 people
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson's Disease
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
- Trial name
- BeyoND (NCT02726386)
- Testing
- ND0612
- Where
- 57 sites in United States, Austria and 7 more
- Volunteers
- 214 people
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease…
- Trial name
- NCT00134251
- Testing
- SLV308
- Where
- 10 sites in Bulgaria, Malta and 1 more
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease
Riluzole to Treat Parkinson's Disease
This study will evaluate the effects of the drug riluzole on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00013624
- Testing
- IV Levodopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease (PD)
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
The purpose of this study is to determine the effect of two different multiple-dose regimens of nebicapone in comparison to placebo and entacapone 200 mg on the pharmacokinetics of levodopa in Parkinson's Disease (PD) patients.
- Trial name
- NCT02834507
- Testing
- BIA 3-202, Comtan®, Sinemet®
- Volunteers
- 19 people
- Sponsor
- Bial - Portela C S.A.
Cocaine Dependence
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient…
- Trial name
- COST (NCT01468012)
- Testing
- levodopa carbidopa and entacapone (LCE)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Parkinson Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease.
- Trial name
- NCT01484990
- Testing
- Levodopa-Carbidopa
- Volunteers
- 19 people
- Sponsor
- AbbVie
Parkinson's Disease
The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)
To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa.
- Trial name
- CALM-PD Cohort (NCT00804479)
- Testing
- No intervention.
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- University of Rochester
Parkinson Disease
Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease
Pilot study: Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug conditions, 30 aged matched control…
- Trial name
- Prodygi-II (NCT03517059)
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Parkinson Disease
Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of four single oral doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa/benserazide 100/25…
- Trial name
- NCT03091543
- Testing
- Madopar® HBS 125, BIA 6-512 25 mg dose, BIA 6-512 50 mg dose
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients
The purpose of this study is to assess the PK of AP-CD/LD given at dose of 50/500mg three times daily compared to CD/LD immediate release (Sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in Parkinson's Disease…
- Trial name
- NCT03576638
- Testing
- Accordion Pill Carbidopa/Levodopa, Sinemet CR 25Mg-100Mg Extended-Release Tablet
- Volunteers
- 12 people
- Sponsor
- Intec Pharma Ltd.
Parkinson Disease (PD), Deep Brain Stimulation
One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease
This study compares the effects of deep brain stimulation (DBS) of the thalamic VIM nucleus versus the subthalamic nucleus (STN) on the levodopa equivalent daily dose (LEDD) in patients with Parkinson's disease.
- Trial name
- VIM vs NST (NCT06936254)
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Central Hospital, Nancy, France
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease .
- Trial name
- NCT05083260
- Testing
- NE3107
- Where
- 16 sites in United States
- Volunteers
- 46 people
- Sponsor
- BioVie Inc.
Parkinson Disease
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the…
- Trial name
- NCT03250117
- Testing
- Ropinirole oral product, Ropinirole Implant
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Titan Pharmaceuticals
Parkinson's Disease
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
- Trial name
- NCT00203034
- Testing
- rasagiline mesylate, 1.0 mg rasagiline mesylate
- Where
- 4 sites in United States
- Volunteers
- 472 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Parkinson's Disease
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1.
- Trial name
- NCT01486628
- Testing
- ND0612
- Where
- Israel
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.